Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Alzheimer's Disease Tau Platform Clinical Trial
NCT06957418Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Aug 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of AADvac1 and Tau2 in Alzheimer's disease (AD) (6 arms). Primary endpoint: Reduction of brain tau deposition at 30 months. Started Jul 2026; status: recruiting.
02
Drugs
AADvac1Tau2
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06957418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957418.